38341PAA0
Gossamer Bio, Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biopharmaceutical company based in San Diego, Gossamer Bio develops treatments for rare diseases like pulmonary arterial hypertension (PAH), a progressive condition of high blood pressure in the lungs. Its lead drug candidate, seralutinib, is an inhaled dry-powder medicine designed to be breathed directly into the lungs. Founded in 2015, the company takes its name from the gossamer thread, meant to symbolize the fragile yet vital connections it builds with patients and partners.
CONVERTIBLEUnderlying: GOSSCUSIP: 38341PAA0HealthcareUS1 derivative reporter
5.00% Convertible Senior Notes due June 1, 2027
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
